SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                ----------------

                                 SCHEDULE 13D
                                (Rule 13d-101)

            INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
           TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
                                 RULE 13d-2(a)

                         (Amendment No. __________ )(1)


                                  XTRANA, INC.
- --------------------------------------------------------------------------------
                                (Name of Issuer)


                    COMMON STOCK, PAR VALUE $0.01 PER SHARE
- --------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                  98415F 10 9
- --------------------------------------------------------------------------------
                                 (CUSIP Number)

                                 JOHN C. GERDES
                                C/O XTRANA, INC.
                         590 BURBANK STREET, SUITE 205
                           BROOMFIELD, COLORADO 80020
                                 (303)466-4424
- --------------------------------------------------------------------------------
                 (Name, Address and Telephone Number of Person
               Authorized to Receive Notices and Communications)


                                AUGUST 10, 2000
- --------------------------------------------------------------------------------
             (Date of Event which Requires Filing of This Statement)

     If the filing  person has  previously  filed a statement on Schedule 13G to
report the  acquisition  that is the subject of this Schedule 13D, and is filing
this  schedule  because  of Rule  13d-1(e),  13d-1(f)  or  13d-1(g),  check  the
following box [_].


          Note:  Schedules filed in paper format shall include a signed original
     and five copies of the schedule, including all exhibits. See Rule 13d-7 for
     other parties to whom copies are to be sent.

                         (Continued on following pages)
                               (Page 1 of 5 Pages)

- ----------
(1)  The  remainder  of this  cover  page  shall be filled  out for a  reporting
     person's  initial  filing on this form with respect to the subject class of
     securities,  and for any subsequent amendment containing  information which
     would alter disclosures provided in a prior cover page.

     The  information  required on the remainder of this cover page shall not be
deemed to be "filed"  for the purpose of Section 18 of the  Securities  Exchange
Act of 1934 or otherwise  subject to the  liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).






CUSIP No. 98415F 10 9                  13D                     Page 2 of 5 Pages


________________________________________________________________________________
1    NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     John C. Gerdes, Ph.D.

________________________________________________________________________________
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                 (a)  [_]
                                                                 (b)  [_]

________________________________________________________________________________
3    SEC USE ONLY



________________________________________________________________________________
4    SOURCE OF FUNDS*

     N/A

________________________________________________________________________________
5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
     PURSUANT TO ITEMS 2(d) OR 2(e)                                   [_]



________________________________________________________________________________
6    CITIZENSHIP OR PLACE OF ORGANIZATION

     United States

________________________________________________________________________________
               7    SOLE VOTING POWER

  NUMBER OF         1,430,068

   SHARES      _________________________________________________________________
               8    SHARED VOTING POWER
BENEFICIALLY
                    0
  OWNED BY
               _________________________________________________________________
    EACH       9    SOLE DISPOSITIVE POWER

  REPORTING         1,430,068

   PERSON      _________________________________________________________________
               10   SHARED DISPOSITIVE POWER
    WITH
                    0

________________________________________________________________________________
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,430,068

________________________________________________________________________________
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

                                                                      [_]

________________________________________________________________________________
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     8.6% (See responses to Items 4 and 5.)

________________________________________________________________________________
14   TYPE OF REPORTING PERSON*


     IN
________________________________________________________________________________
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!




CUSIP No. 98415F 10 9                  13D                     Page 3 of 5 Pages


ITEM 1.       SECURITY AND ISSUER.

         This  Schedule  13D  relates to the Common  Stock,  par value $0.01 per
share (the "COMMON STOCK"),  of Xtrana,  Inc., a Delaware  corporation  formerly
known as Biopool  International,  Inc. (the "ISSUER").  The principal  executive
offices of the Issuer are located at 590 Burbank Street,  Suite 205, Broomfield,
Colorado 80020.

ITEM 2.       IDENTITY AND BACKGROUND.

         This  Schedule  13D is filed on behalf of John C.  Gerdes,  Ph.D.  (the
"REPORTING  PERSON").  The Reporting  Person's principal business address is c/o
Xtrana,  Inc., 590 Burbank Street,  Suite 205,  Broomfield,  Colorado 80020. The
principal  occupation of the Reporting Person is as the Chief Scientific Officer
and a member of the Board of Directors of the Issuer.  The Reporting Person is a
citizen of the United States.

         During the last five years, the Reporting Person has not been convicted
in a criminal  proceeding,  nor has the Reporting Person been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction and as
a result of such  proceeding  was or is subject to a  judgment,  decree or final
order  enjoining  future  violations of, or prohibiting or mandating  activities
subject  to,  federal or state  securities  laws or finding any  violation  with
respect to such laws.

ITEM 3.       SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

         The purpose of this  Schedule 13D is to report the  acquisition  of the
Reporting Person of 1,430,068 shares of Common Stock.

         The source of the  consideration for the acquisition of Common Stock of
the Issuer  reported  hereon was 500,000  shares of the common  stock of Xtrana,
Inc.,  a  privately-held  Delaware  corporation  that  merged  with and into the
Issuer,  effective as of August 10, 2000. On August 10, 2000,  Xtrana,  Inc. was
merged with and into the Issuer,  in  accordance  with an Agreement  and Plan of
Reorganization  dated  May 3,  2000 by and among the  Issuer  and  Xtrana,  Inc.
Pursuant to the merger,  the Issuer  issued shares of Common Stock to the former
stockholders of Xtrana,  Inc.,  including the Reporting  Person, in exchange for
all  outstanding  shares of Xtrana,  Inc.'s  common  stock,  par value $0.01 per
share, and all outstanding shares of Xtrana, Inc.'s Series A, Series B, Series C
and Series D Preferred Stock.

ITEM 4.       PURPOSE OF THE TRANSACTION.

         On August 10,  2000,  Xtrana,  Inc. was merged with and into the Issuer
(known  at the time as  Biopool  International,  Inc.),  in  accordance  with an
Agreement  and  Plan  of  Reorganization  dated  May 3,  2000 by and  among  the
Registrant and Xtrana, Inc. Pursuant to the merger, the Registrant issued shares
of Common Stock in exchange for all outstanding shares of Xtrana,  Inc.'s common
stock, par value $0.01 per share, and all outstanding  shares of Xtrana,  Inc.'s
Series A, Series B, Series C and Series D Preferred  Stock. The aggregate number
of shares of




CUSIP No. 98415F 10 9                  13D                     Page 4 of 5 Pages


Issuer Common Stock that  comprised the merger  consideration  was determined by
extensive  negotiations  between the Issuer and Xtrana, Inc. and was approved by
the Board of  Directors  of the Issuer.  Prior to the merger,  Xtrana,  Inc. had
developed  proprietary nucleic acid (DNA/RNA) testing  technology,  which it had
not yet  commercialized.  In 2001,  the Issuer  changed its corporate  name from
Biopool International, Inc. to Xtrana, Inc.

         The Reporting  Person acquired its shares of Common Stock of the Issuer
for investment purposes.  Except as set forth above, the Reporting Person has no
present plans or proposals which relate to or would result in any of the actions
described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

ITEM 5.       INTEREST IN SECURITIES OF THE ISSUER.

         (a) As of July  14,  2003,  the  Reporting  Person  beneficially  owned
1,430,068 shares of Common Stock, or approximately  8.6% of the shares of Common
Stock  outstanding  (based on  16,533,269  shares of Common  Stock of the Issuer
outstanding on April 23, 2003, as reported on the Issuer's  Quarterly  Report on
Form 10-Q for the quarter ended March 31, 2003).

         (b) The Reporting Person has sole voting power with respect to, and the
sole power to dispose or to direct the disposition  of, the 1,430,068  shares of
the Common Stock he owns.

         (c) Except as set forth above or incorporated  by reference  herein the
Reporting Person has not effected any transaction in the Common Stock during the
past 60 days.

         (d) Not applicable.

         (e) Not applicable.

ITEM 6.       CONTRACTS,  ARRANGEMENTS,  UNDERSTANDINGS  OR  RELATIONSHIPS  WITH
              RESPECT TO SECURITIES OF THE ISSUER.

              Not applicable.

ITEM 7.       MATERIAL TO BE FILED AS EXHIBITS.

              Not applicable.




CUSIP No. 98415F 10 9                  13D                     Page 5 of 5 Pages


                                    SIGNATURE

         After  reasonable  inquiry and to the best of  knowledge  and belief of
each person or entity set forth below, each such person or entity certifies that
the information set forth in this Statement is true, complete and correct.

July 18, 2003                             /s/ John C. Gerdes, Ph.D.
                                          --------------------------
                                          John C. Gerdes, Ph.D.